Semax Peptide: Benefits vs Evidence, Side Effects & Legality

What is Semax?

Semax is a heptapeptide, a chain of seven amino acids, usually described as Met-Glu-His-Phe-Pro-Gly-Pro: an analogue of the ACTH(4-10) fragment of adrenocorticotropic hormone (ACTH). It was developed at Russian research institutes and registered with the Russian Ministry of Health in 1994.

In Russia it is prescribed, usually as a nasal spray, for cerebrovascular indications such as stroke recovery and associated cognitive symptoms. That makes Semax unusual among the peptides on this site: a genuine medicine with a real indication in one country, and an unapproved substance in the US and UK. It has not been submitted for FDA review and holds no MHRA license.

Semax is thought to influence brain-derived neurotrophic factor (BDNF) and other neurochemical systems, which is the basis of its cognitive positioning. Most of the mechanistic and clinical research comes from Russian institutions and often predates modern Western trial standards, which is why its online reputation as a nootropic runs ahead of independently replicated evidence.

Semax is usually researched alongside Selank. Selank is derived from tuftsin, an immune-related peptide, and is registered in Russia for generalized anxiety; Semax is positioned around cognition and stroke recovery. Only Semax is on the US policy's list.

What Semax is used for

• Cognitive-support and focus discussions, where it is the best-known of the 'Russian nootropic' peptides.
• Stroke-recovery and neurological contexts, its actual approved indications in Russia.
• Comparisons with Selank, its anxiety-focused sibling.
• US compounding on prescription, intranasal only, within the interim HHS policy (see legal status below).

Legal status and the US policy's conditions

Claimed benefits vs what the evidence shows

The claims people most often search for about Semax, set against the research. The evidence level names the kind of study a claim rests on: cell (laboratory) studies, animal studies, human studies, or none. Educational only, not medical advice.

Overall: A registered medicine in Russia since 1994 for cerebrovascular indications, supported largely by Russian studies. Large Western-standard randomized trials are lacking, and nootropic use in healthy people is not established. Human data: Real clinical history exists in Russia; independent Western replication is limited and much of the evidence predates modern trial standards.

Semax side effects and risks

What is known

Semax has decades of clinical use in Russia, where it is reported as well tolerated for its approved indications. That report comes from Russian clinical use, not from Western-standard long-term safety studies.

What is not known

Western-standard long-term safety data is limited, and independent Western-standard trials in healthy people are lacking.

Product quality and gray-market vials

Gray-market nasal sprays and vials carry unknown identity, dose and purity, and a 'pharma-grade Semax' claim from a research-chemical seller should be treated with caution. A Semax and Selank combination is outside the US policy, which covers single-ingredient intranasal Semax only. The policy's conditions are under legal status.

Who should take particular care

• Anyone with stroke or other neurological symptoms. Those need medical assessment, and Semax is not an approved treatment for them in the US or UK.
• Tested athletes. Semax is not currently named on the WADA prohibited list, but the list changes every year, so confirm against the current one.
• Anyone offered injectable Semax or a combination spray. Neither is covered by the US policy.

Semax dosage: why this page gives no dose

There is no approved dose of Semax in the US or UK, and its Russian registration does not create one there. Under the US policy a compounded Semax product is made for one named patient on a prescription, as a nasal preparation, so the amount and schedule are set by the prescriber.

Peptide Clinic Finder does not give doses, and this page has no dosing chart. If you have been prescribed it, the amount, form and schedule are the prescriber's and the pharmacy's instructions, not a figure from a website.

• peptide calculator: There is no Semax calculator on this site. The general peptide calculator does arithmetic for a reconstituted vial only, and the form the US policy covers is intranasal.

Is Semax legal? US, UK and sport status

United States

Not FDA-approved and not submitted for FDA review. Under the HHS interim policy announced on October 28, 2026 and published in the Federal Register on October 30, 2026, state-licensed pharmacies, federal facilities and licensed physicians may compound Semax free base for an individual prescription, as the only active ingredient, for intranasal use only, if the policy's conditions are met. Interim enforcement discretion, not approval (checked October 30, 2026).

Source: FDA: Drugs@FDA (openFDA) — no matching approved product · United States · Status verified August 31, 2026

Source: HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Docket HHS-OASH-2026-0496), Federal Register public inspection copy · United States · Published October 30, 2026

What the policy requires: for Semax, the covered form is Semax free base, for intranasal use only. The other conditions in Appendix B are the same for all six peptides it lists: a licensed clinician prescribes it for an individual patient; a state-licensed pharmacy compounds it from bulk ingredient made by an FDA-registered, CGMP manufacturer with a certificate of analysis; the product contains no other active ingredient; the label says it is a compounded drug product, not for resale; and serious adverse events are reported to FDA's MedWatch and to the states involved. The policy does not cover 503B outsourcing facilities, “research use only” products or dietary supplements. Our guide to the October 2026 US peptide policy sets out each condition and its source.

Source: HHS: 503A peptide enforcement discretion policy, Appendix B: conditions and covered routes of administration · United States · Published October 28, 2026 · Accessed October 30, 2026

The same interim policy covers five other peptides, each only on its own and by its own route: KPV peptide (covered for topical or oral use only), TB-500 peptide (covered by subcutaneous or intramuscular injection), Epitalon peptide (covered by subcutaneous or intramuscular injection, dispensed in intermittent courses), BPC-157 peptide (covered by subcutaneous or intramuscular injection, by mouth or on the skin) and MOTS-c peptide (covered by subcutaneous or intramuscular injection).

United Kingdom

Not a licensed UK medicine. No current UK marketing authorization was found for Semax in the MHRA Products register as of August 31, 2026. The HHS policy is US only and changes nothing in the UK or Ireland.

Source: MHRA: MHRA Products register · United Kingdom · Status verified August 31, 2026

Sport (anti-doping)

Not currently named on the WADA prohibited list.

Source: WADA: International Standard — Prohibited List 2026 · International (WADA Code signatories) · In force January 1, 2026

Last reviewed October 30, 2026. Regulatory status can change. Always confirm the current position with a qualified clinician.

Questions to ask a prescriber or clinic about Semax

• Semax isn't approved in this country, so why reference it rather than an approved option?
• What independent, non-Russian evidence supports the use you're describing?
• How do you verify the identity and purity of any product you discuss?

What a credible provider tells you

• A credible provider should distinguish clearly between Semax's Russian approval and its unapproved status in the US and UK.
• Expect honesty that the evidence base is largely Russian and has limited independent Western replication.
• Be cautious of providers presenting it as a proven cognitive enhancer for healthy people, as that use has not been established in trials.

Red flags

• Claims that Semax is a proven cognitive enhancer for healthy people.
• Blurring its Russian approval into an implication it is approved here.
• No discussion of the 2026 US compounding policy (intranasal only, single ingredient, not approval) or sourcing quality.

Semax cost and US availability

There is no regulated UK supply. In the US a state-licensed pharmacy may compound intranasal Semax on prescription under the October 2026 HHS interim policy, but no provider we list sells single-ingredient intranasal Semax (checked October 30, 2026), so we have no price to show. REBL lists a Semax + Selank product, which, as a two-ingredient product, is outside the policy. Anything sold as a research nasal spray carries all the quality uncertainty of gray-market sourcing. If cognitive support is the goal, the more useful comparison is between properly supervised, evidence-based options. See the peptide therapy cost guide. For what the October 2026 HHS policy changed for the six peptides it covers, and whether any provider we list sells each one, read our guide to the October 2026 US peptide policy.

Frequently asked questions about Semax

Related comparisons: Selank vs Semax.